Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Authors
Keywords
Renal cell carcinoma, Cabozantinib, Angiogenesis, VEGF receptor, MET, AXL, RCC
Journal
Current Oncology Reports
Volume 19, Issue 2, Pages -
Publisher
Springer Nature
Online
2017-02-28
DOI
10.1007/s11912-017-0566-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective
- (2016) N. Shenoy et al. ANNALS OF ONCOLOGY
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
- (2016) Le Qu et al. CANCER CELL
- Sunitinib activates Axl signaling in renal cell cancer
- (2016) Johannes C. van der Mijn et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
- (2015) Marie-Therese Haider et al. BONE
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas
- (2015) David Schiff et al. CANCER
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
- (2015) A. Varkaris et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- (2015) Borje Ljungberg et al. EUROPEAN UROLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Axl as a mediator of cellular growth and survival
- (2015) Haley Axelrod et al. Oncotarget
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
- (2014) L. Albiges et al. CLINICAL CANCER RESEARCH
- Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma
- (2014) Rana R. McKay et al. EUROPEAN UROLOGY
- Body mass index and risk of renal cell cancer: A dose-response meta-analysis of published cohort studies
- (2014) Furan Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
- (2014) E. Ciamporcero et al. MOLECULAR CANCER THERAPEUTICS
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)
- (2013) T Wahlgren et al. BRITISH JOURNAL OF CANCER
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
- (2013) Rana R. McKay et al. EUROPEAN UROLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- MET: A Critical Player in Tumorigenesis and Therapeutic Target
- (2013) C. R. Graveel et al. Cold Spring Harbor Perspectives in Biology
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- The Epidemiology of Renal Cell Carcinoma
- (2011) Börje Ljungberg et al. EUROPEAN UROLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis
- (2009) J. Clague et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival
- (2009) A. Gustafsson et al. CLINICAL CANCER RESEARCH
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now